Global Innovative Product Ryaltris® of Grand Pharma Launched in China
Grand Pharma’s subsidiary launched innovative dual‑mechanism nasal spray Ryaltris® in China, filling the clinical gap for allergic rhinitis combination therapies, especially for patients aged 6+. It enriches the firm’s respiratory portfolio and supports standardized, precise treatment while addressing high disease prevalence.
In March 2026, Beijing Grand Johamu Pharmaceutical Co., Ltd., a subsidiary of Grand Pharma (0512.HK), successfully held the launch event for Ryaltris® (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray), a globally innovative original drug. Numerous healthcare professionals gathered to witness the official launch of this innovative therapy in China, bringing new hope to patients suffering from allergic rhinitis.
Allergic rhinitis is a chronic inflammatory disease of the respiratory tract with high global prevalence, which adversely affects patients’ work capacity and quality of life over the long term. Currently, the prevalence of allergic rhinitis in China has risen to 21%, imposing an increasing social and individual burden. While intranasal antihistamines and corticosteroids are the first‑line treatment for allergic rhinitis, most intranasal preparations available in China are mainly single‑ingredient formulations, leaving relatively limited clinical options for combination formulations. In response to this prominent unmet clinical need, the Company has strategically introduced Ryaltris®, an innovative combination nasal spray, to fill this clinical gap.
In the opening address, a specialist in otorhinolaryngology and head and neck surgery stated that pharmacological intervention remains central to clinical diagnosis and treatment in the long‑term management of allergic rhinitis. In recent years, evidence‑based research has clearly demonstrated that the combination of intranasal antihistamines and corticosteroids yields significantly greater clinical benefits in relieving nasal symptoms and controlling inflammation compared to single-agent therapies. The official launch of Ryaltris® as a new dual-mechanism combination formulation aligns with current clinical practice trends, offering a new therapeutic option to optimize the treatment pathways for allergic rhinitis and facilitating more precise and standardized symptom management.
Notably, allergic rhinitis also shows high prevalence and comorbidity rates among children and adolescents in China, significantly affecting their growth, development, and daily life. The launch of Ryaltris® addresses the clinical gap in combination formulations targeting moderate‑to‑severe allergic rhinitis in children aged 6 years and older. It not only delivers comparable therapeutic efficacy in pediatric patients to that in adults but also, with an improved administration experience, helps young patients better adhere to standard treatment, providing a new treatment option for pediatric allergic rhinitis.
Respiratory & critical and severe disease is one of Grand Pharma’s core strategic areas. Currently, the Company’s marketed products cover multiple indications, including rhinitis, bronchitis, asthma, and chronic obstructive pulmonary disease (COPD), forming a comprehensive product portfolio in respiratory disease treatment. Ryaltris®, as a flagship product in the Company’s strategy for treating chronic upper airway diseases, not only enriches the Company’s product portfolio upon its successful launch but also brings a globally leading treatment option to Chinese patients with allergic rhinitis. Going forward, Grand Pharma will continue to place patient needs at the core, increase investment in globally innovative products and advanced technologies to address unmet clinical needs, build a full-lifecycle product portfolio for chronic airway disease management, and contribute further to advancing the high-quality development of airway disease treatment in China.